CJC-1295 & Ipamorelin & GHRP-2 Blend (9mg)

Description

Certificate of Analysis

High Performance Liquid Chromatography

Mass Spectrometry

CJC-1295 & Ipamorelin & GHRP-2 Peptide Blend

CJC-1295, Ipamorelin, and GHRP-2 are all synthetic peptides that are suggested by research teams to potentially stimulate the release of growth hormones. Studies suggest that all three peptides appear synergistic when combined as a blend, potentially providing unique peptide action.

CJC-1295 and Ipamorelin peptides fall under the moniker “growth hormone secretagogues” (GSHs). This implies that these peptides may stimulate the release of growth hormones, but they are not considered growth hormone release peptides (GHRP). Similarly, GHRP-2 is a synthetic peptide analogous to the naturally occurring peptide called Ghrelin.⁽¹⁾ GHRP-2 peptides appear to trigger the release of growth hormones and may possibly increase food intake and metabolism.⁽²⁾

Chemical Makeup ^(3,4,5)

Molecular formula:
CJC-1295: C₁₅₂H₂₅₂N₄₄O₄₂
Ipamorelin: C₃₈H₄₉N₉O₅
GHRP-2: C₄₅H₅₅N₉O₆

Molecular weight:
CJC-1295: 3367.9 g/mol
Ipamorelin: 711.9 g/mol
GHRP-2: 818.0 g/mol

Other known titles:

Ipamorelin

• Ipamorelin Acetate
• IPA

GHRP-2

• Pralmorelin
• Growth hormone-releasing peptide-2

Research and Clinical Studies

 

CJC-1295, Ipamorelin, GHRP-2 Blend, and Growth Hormone Secretagogues (GSHs)

In one clinical trial⁽⁶⁾, the potential of growth hormone secretagogues and growth hormone-releasing peptides in test subjects were studied. Several subjects were presented with the GSHs, after which all the subjects were monitored for any physiological changes. As an outcome of this rigorous study, it was concluded that these peptides appeared to improve growth rates in younger subjects, increasing appetite and improving lean mass in mature subjects. In obese subjects, these peptides were reported to stimulate a possible reduction in bone turnover, potentially also increasing lean mass, and improving their sleep cycle.

 

CJC-1295, Ipamorelin, GHRP-2 Blend and Growth Hormone Deficiencies

Numerous clinical studies have been conducted on test subjects exhibiting growth hormone deficiency. These studies are recorded here for educational and research purposes; studies like these are ongoing and do not offer conclusive evidence of peptide’s potential mechanism of action. In these clinical trials, peptides stimulating growth hormone release appeared to deliver some action in two ways – possibly either via stimulating the pituitary gland to release growth hormones, or possibly acting on the arcuate nucleus of the hypothalamus. While these peptides (including GHRP-2, Ipamorelin, and CJC 1295) appeared to exhibit high releases of growth hormones, it remains unclear which of the two mechanisms worked. In addition, these studies suggested that these peptides may modulate food intake, cardiac tone, and sleep through apparently specific receptor agonistic action.⁽⁷⁾

In another study,⁽⁸⁾ six growth hormone-deficient test subjects facing growth failure were presented with growth hormone-stimulating peptides. All subjects were monitored for episodic growth hormone secretion and toxicity levels during this period. For the duration of the study and short while afterwards, It was observed that there appeared to be a gradual rise in the concentration of growth hormones in all subjects. As per V Mericq et al., the studies suggested that the peptides were “well tolerated and […] stimulate GH secretion.” Studies such as this one are still underway,  and these peptides require further research.

 

CJC-1295, Ipamorelin, GHRP-2 Blend, and Hormones

The primary purpose of this study⁽⁹⁾ was to determine the potential of growth hormone-stimulating peptides on other bodily hormones, like adrenocorticotropic hormone (ACTH), prolactin, and cortisol concentration. The candidates were divided into groups, presented the peptides, and the results were compared. It was observed that the growth hormone levels in both groups appeared to increase significantly after peptide presence, with the concentration appearing to be higher in the younger subjects compared to the mature test subjects.

 

CJC-1295, Ipamorelin, GHRP-2 Blend, and Food Intake

In this clinical study,⁽¹⁰⁾ test subjects were presented with growth hormone release-stimulating peptides and then presented with unlimited food supply to measure food intake. It was reported that the subjects with peptide presence ate approximately 36% more than the control subjects did. In addition, the growth hormone levels were reportedly increased in these subjects, suggesting the action the peptides had on both food intake and growth hormone levels. As per this study, the growth hormone release-stimulating peptides appeared to be a “valuable tool for investigating the effects on eating behavior.” Research studies are still ongoing to fully explore the potential of peptide blends.

 

CJC-1295 & Ipamorelin & GHRP-2 Peptide Blend is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

 

---

---

References:

Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2019 Oct 7]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com https://www.ncbi.nlm.nih.gov/books/NBK279163/
Laferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824650/
National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC.
National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.
National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 6918245, Pralmorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Pralmorelin.
Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/
Rogério G. Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694.
Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60. https://pubmed.ncbi.nlm.nih.gov/9661608/
Emanuela Arvat, Lidia Di Vito, Barbara Maccagno, Fabio Broglio, Muni F Boghen, Romano Deghenghi, Franco Camanni, Ezio Ghigo, Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH, Peptides, Volume 18, Issue 6, 1997, Pages 885-891, ISSN 0196-9781, https://doi.org/10.1016/S0196-9781(97)00016-8
Laferrère, Blandine et al. “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.” The Journal of clinical endocrinology and metabolism vol. 90,2 (2005): 611-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824650/

---

NOTE: These products are intended for laboratory research use only. CJC-1295 Ipamorelin GHRP2 blend for sale is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.